Item 6. SELECTED FINANCIAL DATA

3K characters. Original on sec.gov · Markdown

Item 6. SELECTED FINANCIAL DATA

The selected financial information should be read in conjunction with the financial statements and accompanying notes included under Item 8, "Financial Statements and Supplementary Data" and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations."



as of and for the years ended December 31 (in millions, except per share data)	2019		2018		2017		2016		2015
Statement of earnings data
Net revenues	$	33,266	$	32,753	$	28,216	$	25,638	$	22,859
Net earnings	7,882		5,687		5,309		5,953		5,144
Basic earnings per share	$	5.30	$	3.67	$	3.31	$	3.65	$	3.15
Diluted earnings per share	$	5.28	$	3.66	$	3.30	$	3.63	$	3.13
Cash dividends declared per common share	$	4.39	$	3.95	$	2.63	$	2.35	$	2.10
Weighted-average basic shares outstanding	1,481		1,541		1,596		1,622		1,625
Weighted-average diluted shares outstanding	1,484		1,546		1,603		1,631		1,637
Balance sheet data
Total assets (a)	$	89,115	$	59,352	$	70,786	$	66,099	$	53,050
Long-term debt and finance lease obligations (a)(b)	66,728		36,611		36,968		36,465		31,265


(a)	In November 2019, AbbVie issued $30.0 billion aggregate principal amount of floating rate and fixed rate unsecured senior notes at maturities ranging from 18 months to 30 years. AbbVie expects to use the net proceeds to fund a portion of the aggregate cash consideration due to Allergan shareholders in connection with the proposed acquisition and to pay related fees and expenses. See Note 5 to the Consolidated Financial Statements for information regarding the proposed acquisition and Note 10 for information on the senior notes.

(a)

In November 2019, AbbVie issued $30.0 billion aggregate principal amount of floating rate and fixed rate unsecured senior notes at maturities ranging from 18 months to 30 years. AbbVie expects to use the net proceeds to fund a portion of the aggregate cash consideration due to Allergan shareholders in connection with the proposed acquisition and to pay related fees and expenses. See Note 5 to the Consolidated Financial Statements for information regarding the proposed acquisition and Note 10 for information on the senior notes.


(b)	Includes current portion of both long-term debt and finance lease obligations.



		2019 Form 10-K \| 25

Previous: Item 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES · Next: Item 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS